Clinical Trial Update: Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement [Phase 1]

View source ↗

Summary

Phase 1 study of AS902330 (recombinant human fibroblast growth factor-18) administered intra-articularly in knee osteoarthritis patients eligible for knee repla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis

Drugs mentioned

• AS902330 (fibroblast growth factor-18)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Knee Osteoarthritis | Phase 1 | Status: COMPLETED